Genocea Biosciences (NASDAQ:GNCA) and Microbot Medical (NASDAQ:MBOT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, earnings, institutional ownership and profitability.
Risk and Volatility
Genocea Biosciences has a beta of 2.42, indicating that its stock price is 142% more volatile than the S&P 500. Comparatively, Microbot Medical has a beta of 4.99, indicating that its stock price is 399% more volatile than the S&P 500.
This is a breakdown of current recommendations for Genocea Biosciences and Microbot Medical, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Genocea Biosciences currently has a consensus price target of $16.33, indicating a potential upside of 625.93%. Microbot Medical has a consensus price target of $10.00, indicating a potential upside of 102.02%. Given Genocea Biosciences’ higher probable upside, analysts clearly believe Genocea Biosciences is more favorable than Microbot Medical.
Insider and Institutional Ownership
52.9% of Genocea Biosciences shares are owned by institutional investors. Comparatively, 14.3% of Microbot Medical shares are owned by institutional investors. 2.3% of Genocea Biosciences shares are owned by company insiders. Comparatively, 14.5% of Microbot Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Earnings and Valuation
This table compares Genocea Biosciences and Microbot Medical’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Genocea Biosciences||$230,000.00||255.82||-$27.81 million||($3.68)||-0.61|
|Microbot Medical||N/A||N/A||-$7.24 million||($2.41)||-2.05|
Microbot Medical has lower revenue, but higher earnings than Genocea Biosciences. Microbot Medical is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.
This table compares Genocea Biosciences and Microbot Medical’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Microbot Medical beats Genocea Biosciences on 6 of the 11 factors compared between the two stocks.
About Genocea Biosciences
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. Its lead immuno-oncology program is GEN-009, an adjuvanted neoantigen peptide vaccine candidate, which is in preclinical stage, designed to direct a patient's immune system to attack tumor. The company is also seeking partners to develop cancer vaccines targeting tumor-associated antigens and a vaccine targeting cancers caused by Epstein-Barr virus. Genocea Biosciences, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.
About Microbot Medical
Microbot Medical Inc., a pre-clinical medical device company, researches, designs, and develops micro-robotics assisted medical technologies targeting the minimally invasive surgery space. The company, through its ViRob and TipCAT micro-robotic technologies, is developing two product candidates, including the Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; and a self-propelling, semi-disposable endoscope, which is used in colonoscopy procedures. It also holds an intellectual property portfolio that comprises 9 patent families, which include 9 patents granted in the United States, 12 patents granted outside the United States, and 15 patent applications pending worldwide. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts.
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.